Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Perindopril arginine
McDermott Laboratories Ltd., T/A Gerard Laboratories
C09AA; C09AA04
Perindopril arginine
10 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
ACE inhibitors, plain; perindopril
Not marketed
2011-06-23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PERINDOPRIL ARGININE MYLAN 2.5 MG FILM-COATED TABLETS PERINDOPRIL ARGININE MYLAN 5 MG FILM-COATED TABLETS PERINDOPRIL ARGININE MYLAN 10 MG FILM-COATED TABLETS perindopril arginine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Perindopril arginine Mylan is and what it is used for 2. What you need to know before you take Perindopril arginine Mylan 3. How to take Perindopril arginine Mylan 4. Possible side effects 5. How to store Perindopril arginine Mylan 6. Contents of the pack and other information 1. WHAT PERINDOPRIL ARGININE MYLAN IS AND WHAT IT IS USED FOR Perindopril arginine Mylan belongs to a group of medicines known as angiotensin converting enzyme (ACE) inhibitors. These work by making your blood vessels wider, which makes it easier for your heart to pump blood through them. Perindopril arginine Mylan is used: to treat high blood pressure (hypertension) to treat heart failure (a condition where the heart is unable to pump enough blood to meet the body’s needs) [_for 2.5 mg & 5 mg only_] to reduce the risk of cardiac events, such as heart attack, in patients with stable coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) and who have already had a heart attack and/or an operation to improve the blood supply to the heart. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PERINDOPRIL ARGININE MYLAN DO NOT TAKE PERINDOPRIL ARGININE MYLAN if you are allergic to perindopril, any other AC Read the complete document
Health Products Regulatory Authority 25 January 2021 CRN008W57 Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Perindopril arginine Mylan 10 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg of perindopril arginine, equivalent to 6.790 mg of perindopril. Excipients with known effect: Contains lecithin (soya) Each tablet contains 135.80 mg of lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Green, round, biconvex, film-coated tablets debossed with “PA3” on one side and “M” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypertension: treatment of hypertension. Stable coronary artery disease: reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose should be individualised according to the patient profile (see section 4.4) and blood pressure response. Hypertension Perindopril arginine Mylan may be used in monotherapy or in combination with other classes of anti-hypertensive therapy (see sections 4.3, 4.4, 4.5 and 5.1). The recommended starting dose is 5 mg given once daily in the morning. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A starting dose of 2.5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. The dose may be increased to 10 mg once daily after one month of treatment. Symptomatic hypotension may occur following initiation of therapy with Perindopril arginine Mylan; this is more likely in patients who are being treated concurrently with diuretics. Caution is therefore recommended since these patients may be volume and/or salt depleted. If possible, the diuretic Read the complete document